ACSL4 and familial pancreatic carcinoma: To further verify whetherNCOA6 knockdown increases the RSL3 sensitivity of pancreatic cancer cells through the upregulation of ACSL4 expression, we treated pancreatic cancer cells with rosiglitazone (20 μm), a pharmacological inhibitor of ACSL4, and found that it restored the viability of the RSL3-treated cells to a certain extent (Figure 3F).